ArticleCancer immunology, immunotherapy : CII2024

Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity.

Jiawei Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.